Considering the high expression of Fn14 in tumor cells and the specific affinity of TWEAK to Fn14, the conjugate of TWEAK to an Fn14 or cIAP1 inhibitor (e.g., MV1) might be a promising strategy for the treatment of malignant tumors. This evidence concerns the gene BIRC2 and neoplasm.